

Current role of platinum-based chemotherapy in advanced ovarian cancer

Wichai Termrungruanglert* Damrong Tresukosol*
Tul Sittisomwong* Nakorn Sirisabya*

Termrungruanglert W, Tresukosol D, Sittisomwong T, Sirisabya N. Current role of platinum-based chemotherapy in advanced ovarian cancer. *Chula Med J* 1997 Mar;41(3): 199-210

Objective : *To present the overview of current role of platinum-based chemotherapy in advanced ovarian cancer.*

Setting : *A computerized search of articles published through December 1996 was performed on the Medline and Cancerlit data base. Additional sources were identified through cross-referencing.*

Method : *All identified references were reviewed with particular attention to their relevance to platinum-based chemotherapy in advanced ovarian cancer.*

Conclusion : *Platinum-based chemotherapy remains the standard treatment in advanced ovarian cancer. Carboplatin appears to be equivalent in activity to cisplatin in the treatment of ovarian cancer.*

Key words : *Cisplatin, Carboplatin, Platinum, Ovarian cancer.*

Reprint request : Termrungruanglert W, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.

Received for publication. January 2, 1997.

วิจัย เติมรุ่งเรืองเลิศ, ดำรง ตรีสุโกศล, ดุลย์ สิทธิสมวงศ์, นคร ศิริทรัพย์. บทบาทปัจจุบันของเคมีบำบัดกลุ่มพลาตินัมในการรักษามะเร็งรังไข่ระยะลุกลาม. จุฬาลงกรณ์เวชสาร 2540 มี.ค.;41(3): 199-210

- วัตถุประสงค์ : เพื่อนำเสนอบทบาทปัจจุบันของเคมีบำบัดกลุ่มพลาตินัมในการรักษามะเร็งรังไข่ระยะลุกลาม
- วิธีการวิจัย : รวบรวมผลการศึกษาเกี่ยวกับเคมีบำบัดกลุ่มพลาตินัมในการรักษามะเร็งรังไข่ระยะลุกลามจากการสืบค้นทางคอมพิวเตอร์ในระบบข้อมูล Medline และ Cancerlit จนถึงเดือนธันวาคม 2539 ประมวลเปรียบเทียบข้อมูลและนำเสนอตลอดจนวิเคราะห์ผลการศึกษาดังกล่าว
- สรุป : เคมีบำบัดกลุ่มพลาตินัม ยังเป็นกลุ่มยามาตรฐานหลักในการรักษามะเร็งรังไข่ระยะลุกลาม Carboplatin มีประสิทธิภาพเทียบเท่า Cisplatin ในการรักษามะเร็งรังไข่

For the majority of patients presented with advanced ovarian cancer (stage III or IV) the standard treatment has been cytoreductive surgery (or debulking surgery) to remove the primary tumor as well as the associated metastatic disease, and to determine accurately the extent of disease, followed by combination chemotherapy. However, with advanced disease patients, the volume of residual disease is a critical determinant of patient response to the chemotherapy as well as their survival.⁽¹⁾ Systemic chemotherapy is the standard treatment for advanced epithelial ovarian cancer.⁽²⁾ Oral single-agent alkylating therapy had been used for many years⁽³⁾ but the introduction of cisplatin in the latter half of the 1970s changed the therapeutic approach for the most frequently used treatment regimen in the United States. Recently, paclitaxel has become available, and its combination with other drugs is now in use. The use of single-agent chemotherapy which is less toxic for metastatic epithelial ovarian cancer is generally reserved for patients whose overall physical condition precludes the use of more toxic combinations therapy, such as elderly or debilitated patients.

In this article, we will focus on the current role of platinum-based chemotherapy in advanced ovarian cancer treatment.

Combination Chemotherapy

The relatively large number of active drugs available for epithelial ovarian cancer treatment points to the potential for the development of

effective combination therapy. Combination chemotherapy has been shown to be superior to single-agent therapy in most patients with advanced ovarian cancer.⁽⁴⁾ The first study to show the benefits with combination therapy compared a Hexa-CAF (hexamethylmelamine, Cytosan, methotrexate, 5-FU) regimen with melphalan and showed that the response rates and the median survival rates with the combination regimen were better than with the single drug.⁽⁵⁾ The Hexa-CAF regimen produced a complete response rate of 33% with a median survival of 29 months, compared with 16% and 17 months, respectively, for melphalan. A variety of combination chemotherapeutic regimens have been studied for the treatment of advanced epithelial ovarian cancer. A summary of the most common regimens is presented in Table 1.

Platinum-based Combination Chemotherapy

The platinum compounds remain one of the most active drugs in epithelial ovarian cancer treatment since they were first introduced into clinics in the late 1970s.⁽⁶⁾ Cisplatin, the most extensively studied platinum compound has clear-cut activity in patients with no prior chemotherapy, as well as in those who have received prior alkylating agents.^(7,8) Subsequently, it has been incorporated into combination chemotherapeutic regimens with other active drugs, like cyclophosphamide, hexamethylmelamine, and doxorubicin. One such regimen, CHAP (Cytosan, hexamethylmelamine, adriamycin, cisplatin), was

Table 1. Chemotherapeutic regimens for advanced ovarian cancer.

	Regimen	Interval
PC	Cisplatin (75-100 mg/m ²) Cyclophosphamide (650-1000 mg/m ²)	Q 3 weeks
CC	Carboplatin (AUC = 5-7) Cyclophosphamide (600 mg/m ²)	Q 4 weeks
PAC	Cisplatin (50 mg/m ²) Adriamycin 50 mg/m ² Cyclophosphamide (500 mg/m ²)	Q 3-4 weeks
CHAP	Hexamethylmelamine 150 mg/m ² orally days 1-14 Cyclophosphamide 350 mg/m ² IV day 1 and day 8 Adriamycin 20 mg/m ² IV day 1 and day 8 Cisplatin 60 mg/m ² IV day 1	Q 3-4 weeks
PT	Cisplatin (75-100 mg/m ²) Taxol (135-210 mg/m ²)	Q 3 weeks
CT	Carboplatin (starting dose, AUC = 5) Taxol (135-175 mg/m ²)	Q 3-4 weeks

AUC = area under the curve

shown to be active and generally tolerable.⁽⁹⁾ Because of the toxicity of hexamethylmelamine, particularly the depression that some patients experience with the drug, many oncologists omitted that agent.

In a meta-analysis on studies of patients with advanced stage disease, those given cisplatin-containing combination chemotherapy were compared with those treated with regimens that did not include cisplatin.⁽⁴⁾ Survival differences between the groups were noted for 2 to 5 years, with the

cisplatin group having a slight survival advantage, but the difference disappeared by 8 years.⁽⁴⁾ At a consensus meeting on the treatment of advanced ovarian cancer, there was agreement that after appropriate cytoreductive surgery, platinum-based chemotherapy yields superior response rates, progression-free survival, and superior survival rates.⁽¹⁰⁾

The addition of doxorubicin to cisplatin and cyclophosphamide regimens is another interesting issue. The recent consensus⁽¹¹⁾ is that

either cyclophosphamide (750 mg/m²) plus cisplatin (75 mg/m²) every 3 weeks or cyclophosphamide (500 mg/m²) plus doxorubicin (50 mg/m²) plus cisplatin (50 mg/m²) (CAP) every 3 weeks is acceptable standard therapy. However, four prospective randomized trials⁽¹²⁻¹⁵⁾ comparing cisplatin and cyclophosphamide with the CAP regimen failed to show statistically significant differences in overall survival. The largest of the above trials was that of the Italian Cooperative Gynecologic Oncology Group (GICOG), which randomized 529 patients to receive CAP, cisplatin/cyclophosphamide (PC), or single-agent cisplatin⁽¹²⁾ No statistical difference was seen in overall survival (5 years minimum follow-up) among the three groups. Meta-analysis of the above four trials⁽¹⁶⁾ revealed a 6-year survival advantage of 7% in patients receiving the doxorubicin containing regimen, but it remains unclear whether the benefit was a result of doxorubicin or the greater dose intensity reached by adding it. Gadducci et al reported their update data which revealed no significant difference in PFS between the PC and CAP regimens. However, there is a trend in favor of the CAP regimen among patients with residual disease >2 cm.⁽¹⁷⁾ Because of the cardiotoxicity of doxorubicin, it would be desirable to omit the drug if overall response rates were not significantly changed. A large prospective randomized Dutch study of CHAP versus PC showed that response rates and median survival rates were almost identical.⁽¹⁸⁾ Because the toxicity of PC was

significantly less than that of the four-drug treatment, it was concluded that PC should be considered the treatment of choice.

Another controversial issue is the number of cycles of chemotherapy to be given. Most studies report 5 to 10 courses of treatment, and it is generally agreed that most response occurs within four courses of chemotherapy. Two prospective randomized trials failed to demonstrate any significant benefit for more prolonged treatment.^(19,20) The current recommendation is to give at least six courses of treatment. There is no evidence so far to show that additional treatment produces any benefit.

Cisplatin Dose Intensity

The importance of dose intensity (mg/m²/time period) in relation to clinical outcome in ovarian cancer has been analyzed by several investigators. At present, the published data from the randomized trials of dose intensity for ovarian cancer have failed to confirm a benefit in favor of the dose-intense approach.⁽²¹⁻²⁹⁾ The large Scottish trial⁽²¹⁾ showed a difference in survival but included in its population optimally debulked patients with stage IC to IV disease. Recently, the mature results of this group showed the overall survival rates for high-dose and low-dose arm were 32.4% and 26.6%, respectively, and the overall relative death rate was 0.68 (P=0.043).⁽²²⁾ This represents a reduction in overall benefit with longer follow-up compared with the first 2 years of study (relative death rate of 0.52).

Toxicity, particularly neurotoxicity, was still evident in the fourth year (10/31 on HD compared with 1/24 on LD). A Hong Kong trial included stage III to IV patients who showed improved survival with high-dose regimens, but the patient population was small.⁽²³⁾

The Gynecologic Oncology Group (GOG) trial of patients with suboptimal stage III disease failed to demonstrate survival advantage for the high-dose chemotherapy arm.⁽²⁴⁾ However, it is

important to note that the final assessment of clinical response was based on a relatively small subset of patients with measurable disease (34%), and that in this study the high-intensity arm consisted of only four courses of chemotherapy (Table 2).^(12,20-28) It is possible that a greater increase in dose intensity was required to produce clinically meaningful improvement in patients with advanced disease. A critical problem; however, with evaluation of dose intensity in ovarian

Table 2. Randomized trials of cisplatin/cyclophosphamide dose intensity.

Group	Disease stage	Number of patients	Drug Regimens	Dose intensity	Cumulative dose	Assigned increase in dose intensified arm	Results
Hong Kong (23)	Stage III/IV	60	Cisplatin 100 mg/m ² + CTX 1,000 mg/m ² vs cisplatin 50 mg/m ² + CTX 1,000 mg/m ² x 6 cycles	+	+	x 2	3-year survival rates: higher dose = 60% lower dose = 30%
GOG (24)	Untreated suboptimal stage III/IV	458	Cisplatin 100 mg/m ² + CTX 1,000 mg/m ² x 4 vs cisplatin 50 mg/m ² + CTX 500 mg/m ² x 8	+	-	x 2	Median survival duration: higher dose = 21.9 m. lower dose = 18.9 m.
Scottish (21)	Stage I-IV	165	Cisplatin 100 mg/m ² + CTX 750 mg/m ² vs Cisplatin 50 mg/m ² + CTX 750 mg/m ² x 6 cycles	+	-	x 2	Median survival duration: higher dose = 28.5 m. lower dose = 17.2 m
Italian (12)	Stage III/IV	296	Cisplatin 75 mg/m ² every 3 wk x 6 vs cisplatin 50 mg/m ² every wk x 9 cycles	+	-	x 2	Median survival duration: higher dose = 36 m. lower dose = 33 m.
Danish (20)	Stage II-IV	78	AUC escalation from: 3-8 mg/ml/min	+	+	AUC x 4 vs AUC x 8	Higher PCR survival too early for analysis

CTX = cyclophosphamide, PCR = pathologic complete response

cancer is that multiple chemotherapy related toxicities preclude marked increases in dose intensity for prolonged periods.

Those studies that focused on patients with suboptimally debulked disease consistently reported negative results regarding statistically significant improvements in response rates and overall survival. Studies focusing on patients with optimally debulked disease have reported positive and negative points both in terms of response rate and overall survival. Dose intensity should thus be more likely to lead to enhanced survival in small-volume disease.

Carboplatin versus Cisplatin

Carboplatin, the second-generation platinum analogue, was developed and introduced to have less toxicity than its parent compound, cisplatin. Carboplatin was shown to have lower toxicity with fewer gastrointestinal side effects, especially nausea and vomiting, less neurotoxicity, less nephrotoxicity and less ototoxicity but more thrombocytopenia than cisplatin.⁽³⁰⁻³³⁾

The issue of carboplatin VS. cisplatin remains one of the most common concerns in treating ovarian cancer. A meta-analysis was conducted by the Advanced Ovarian Cancer Trialist Group (AOCTG)⁽⁴⁾ that incorporated data from over 2,000 patients. When it compared carboplatin and cisplatin treatment groups, it failed to demonstrate any significant differences in overall survival between the two groups, and a similar conclusion came from two large North

American trials: a trial by the Southwest Oncology Group⁽³²⁾ (342 patients with stage III or IV disease randomized to receive cisplatin, 100mg/m², plus cyclophosphamide, 600 mg/m², or carboplatin, 300 mg/m², plus cyclophosphamide 600 mg/m²) and a trial by the National Cancer Institute of Canada⁽³³⁾ (447 patients randomized to receive cisplatin 75 mg/m², plus cyclophosphamide vs. carboplatin/cyclophosphamide). All three of these trials failed to demonstrate a significant difference in overall survival rates, though the carboplatin regimen was found to have a better therapeutic index and to produce a better quality of life.^(32,33) In contrast, a recent French trial⁽³⁴⁾ involving 144 patients with stage III or IV disease who received either cisplatin or carboplatin demonstrated very different results, as seen in^(30,32-37). The doses of cyclophosphamide (500 mg/m²) and doxorubicin (40 mg/m²) were the same in both groups. The pathologic complete remission and overall response rates were significantly higher in the cisplatin arm than in the carboplatin arm (33% vs. 15% and 73% vs. 47%, respectively). The median survival time was 27.9 months for the cisplatin arm and 20.6 months for the carboplatin arm. The actual delivered dose intensity of the drugs in the two arms was not reported.⁽³⁴⁾

At the recent National Institutes of Health Consensus Conference on Ovarian Cancer,⁽³⁸⁾ it was concluded that data from mature randomized clinical trials have indicated that the combination of carboplatin and cyclophosphamide is effective

Table 3. Carboplatin vs Cisplatin in combination chemotherapy for advanced ovarian cancer: treatment results.

Group (ref)	No.of patients	Carb/Cis Dose (mg/m ²)	Carb/Cis PDI (mg/m ² /wk)	Combine w/Drug	SOD(%)	Carb/Cis PCR	Carb/Cis Median PFS (mos.)	Carb/Cis Median surv (mos.)
NCIC (33)	417	300/75	75/18.75	CTX	59 (1)	11/15	13.4/12.9	25.8/23.8
EORTC (30)	342	350/100	70/20	DOX CTX HMM	63 (2)	23/27	13.1/16.8	22.7/24.6
SWOG (33)	291	300/100	75/25	CTX	100 (1)	8/7	N/A	19.8/17.4
GONO (35)	164	200/50	50/12.5	DOX CTX	66 (1)	14/20	15.5/13.2	23.1/22.6
ARTAC (34)	144	300/75	75/18.75	DOX CTX	N/A	10/25	N/A	20.6/27.9
NCCTG /Mayo (36)	103	150/60	37.5/15	CTX	35 (1)	N/A	12.0/17.0	20.0/27.0
UK (37)	56	300/100	75/25	CTX	77 (1)	N/A	24.0/13.0	24.0/19.0

PDI = Planned dose intensity, 20 mg/m²/day* 5, DOX: doxorubicin; CTX: cyclophosphamide;

HMM : hexamethylmelamine; SOD: suboptimally debulked; PCR: pathologic complete response;

PFS : progression-free survival; N/A: not available.

(1) : lesions>2 cm; (2): lesions>1 cm.

therapy, and the substitution of carboplatin for cisplatin leads to reduced toxicity.

In summary, platinum-base chemotherapy remains the standard treatment in advanced ovarian cancer. Carboplatin appears to be equivalent in activity to cisplatin in the treatment of ovarian cancer.^(6,38-40) The two-drug combination of cyclophosphamide and cisplatin or carboplatin results in 60% to 80% overall response rate and 40% to 50% clinical complete response.

References

1. Thigpen JT. Chemotherapy in the management of celomic epithelial carcinoma of the ovary. In: Markman M, Hoskins WJ, eds. *Cancer of the Ovary*. New york: Raven Press, 1993:277-86
2. Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, eds. *Practical Gynecologic Oncology*. 2nd ed. Baltimore, William and Wilkins, 1994:327-75

3. Smith JP, Day TG. Review of ovarian cancer at the University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute. *Am J Obstet Gynecol* 1979 Dec 1;135(7):984-93
4. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. *Br Med J* 1991;303:884-93
5. Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GI, DeVita VT Jr. Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. *N Engl J Med* 1978 Dec 7;299(23):1261-6
6. Ozols RF. Current status of chemotherapy for ovarian cancer. *Semin Oncol* 1995 Oct; 22(5 Suppl 12):61-6
7. Wiltshaw E, Kroner T. Phase II study of cis-dichlorodiammine platinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. *Cancer Treat Rep* 1976 Jan; 60(1):55-60
8. Thigpen T, Blessing JA, Homesley H, Lagasse L. Cisplatin in the treatment of advanced or recurrent adenocarcinoma of the ovary. Cis - A phase II study of the Gynecologic Oncology Group. *Am J Clin Oncol* 1983 Aug;6(4):431-5
9. Greco FA, Julian CG, Richardson RL, Burnett L, Hande KR, Oldham RK. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation. *Obstet Gynecol* 1981 Aug; 58(2):199-205
10. Allen DG, Baak J, Belpomme D, Berek JS, Bertelsen K, ten Bokkel Hninink WW, van der Burg ME, Calvert AH, Conte PF, Dauplat J. Advanced epithelial ovarian cancer: 1993 consensus statement. *Ann Oncol* 1993;4 Suppl: S83-S89
11. Ozols RF. Ovarian cancer: Part II. Treatment. *Curr Probl Cancer* 1992 Mar-Apr; 16:61-126
12. GICOOG (Gruppo Interegionale Cooperativo Oncologico Gynecologica): Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. *Lancet* 1989 Aug 15; 2(8555) :353-9
13. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. *J Clin Oncol* 1989 Apr;7(4):457-65
14. Bertelsen K, Jacobsen A, Andersen JE, Pedersen PH, Ahrons S, Kiaer H, Arffmann E, Bichel P, Boestofte E, Stroyer I. A randomized study of cyclophosphamide and cisplatin with or without doxorubicin in advanced ovarian cancer. *Gynecol Oncol* 1987 Oct;26(2):161-9

15. Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. *J Clin Oncol* 1986 Jun;4(6):965-71
16. The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. *J Clin Oncol* 1991 Sep;9 (9):1668-74
17. Gadducci A, Bruzzone M, Carnino F. Twelve-year follow-up of a randomized trial comparing cisplatin and cyclophosphamide with cisplatin, doxorubicin and cyclophosphamide in patients with advanced epithelial ovarian cancer. *Int J Gynecol Cancer* 1996; 6:286-90
18. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Heintz AP, van Lent M, Trimbos JB, Bouma J, Vermorken JB. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 versus CP) in advanced ovarian carcinoma: A randomized trial of the Netherlands joint study group for ovarian cancer. *J Clin Oncol* 1987 Aug;5 (8):1157-68
19. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, Chapman D, Almadrones L, Lewis JL Jr. Randomized prospective trial of 5 vs. 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. *Gynecol Oncol* 1992;45:284-9
20. Bertelsen IF, Jacobsen A, Hansen MK, et al: A randomized trial of six vs. twelve cycles of cyclophosphamide, Adriamycin, in advanced ovarian cancer (abstract). *Proc Am soc Clin Oncol* 1989; 8:15
21. Kaye SB, Lewis CR, Paul JP, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. *Lancet* 1992 Aug 8;340 (8815):329-33
22. Kaye SB, Cassidy J, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. *Scottish gynaecology Cancer Trial Group. J Clin Oncol* 1996 Jul;14 (7): 2113-9
23. Ngan HY, Choo YC, Cheung M, Wong LC, Ma HK, Collins R, Fung C, Ng CS, Wong V, Ho HC. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. *Hong Kong Ovarian Carcinoma Study Group. Chemotherapy* 1989;35(3):221-7

24. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J. Assessment of dose intensive therapy in suboptimally debulked ovarian cancer. A Gynecologic Oncology Group study. *J Clin Oncol* 1995;13(7):1589-99
25. Bella M, Cocconi G, Lotticci, et al. Conventional versus high dose intensity regimen of cisplatin in advanced ovarian carcinoma. A prospective randomized study. *Proc Am Soc Clin Oncol* 1992; 11:223
26. Ehrlich CE, Einhorn L, Stehman FB, Blessing J. Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cyclophosphamide. The Indiana University experience. *Clin Obstet Gynecol* 1983 Aug; 10 (2):325-35
27. Colombo N, Pittelli MR, Parma G, et al. Cisplatin dose-intensity in advanced ovarian cancer: a randomized study of dose-intensity versus standard dose cisplatin monotherapy. *Proc Am Soc Clin Oncol* 1993;12:255
28. Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, Boccardo F, Brunetti I, Catsafados E, Chiara S. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epirubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. *J Clin Oncol* 1996 Feb;14(2) :351-6
29. Fennelly D. Dose intensity in advanced ovarian cancer: have we answered the question? *Clin Cancer Res* 1995;1: 575-82
30. Ten Bokkel Huinink WW, van der Burg MET, van Oosterom AT, Neijt JP, George M, Guastalla JP, Veenhof CH, Dalesio D, Rotmenze N, Vermorken JB. Carboplatin in combination therapy for ovarian cancer. *Cancer Treat Rev* 1988 Jun;15 Suppl B:9-15
31. Calvert AH, Newall DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol* 1989 Nov;7(11): 1748-56
32. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvya VK, Nahhas WA, Jolles CJ. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III (suboptimal) and IV ovarian cancer. *J Clin Oncol* 1992 May;10(5): 706-17
33. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stainmir R, O'Connell G, MacLean G. Cisplatin cyclophosphamide versus car-

- boplatin cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1992 May;10(5):718-26
34. Belpomme D, Bugat R, Rives M, et al. Carboplatin vs. cisplatin in association with cyclophosphamide and doxorubicin as first line therapy in stage III-IV ovarian carcinoma: Results of an ARTAC phase III trial. *Proc Am Soc Clin Oncol* 1992; 11:227
35. Conte PF, Bruzzone M, Carnino F, Chiara S, Donadio M, Facchini V, Fioretti P, Foglia G, Gadducci A, Gallo L. Carboplatin, doxorubicin, and cyclophosphamide vs. cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. *J Clin Oncol* 1991 Apr;9(4):658-63
36. Edmonson JH, McCormack GM, Wieand HS, Kugler JW, Krook JE, Stanhope CR, Everson LK, Lawrie JA, Ebbert LP, Malkasian GD. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. *J Natl Cancer Inst* 1989 Oct 4;81(19) :1500-4
37. Gurney H, Crowther D, Anderson H, Murphy D, Prendiville J, Ranson M, Mayor P, Swindell R, Buckley CH, Tindall VR. Five-year follow-up and dose delivery analysis of cisplatin, iproplatin, or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. *Ann Oncol* 1990 Nov;1(6):427-33
38. NIH Consensus Conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. *JAMA* 1995 Feb 8; 273(6):491-97
39. Alberts DS. Carboplatin versus cisplatin in ovarian cancer. *Semin Oncol* 1995 Oct; 22(5 Suppl 12):88-90
40. Mainwaring PN, Gore ME. The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer. *Anti-Cancer Drugs* 1995 Oct;6(Suppl 5):29-41